Xenetic Biosciences M&A Deal with Santersus AG
Xenetic Biosciences provided a status update on its pending all-stock acquisition of Santersus AG, which is expected to transform the company into a clinical-stage entity focused on targeting neutrophil extracellular traps (NETs). The combined company will feature a pipeline with four first-in-class programs, including pivotal-stage programs in sepsis and SLE that have received FDA Breakthrough Device Designation.
- Counterparty
- Santersus AG
“This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer
“We believe the complementary nature of NucleoCapture® and Xenetic's DNase platform provides a differentiated opportunity to address NETs through distinct mechanisms, potentially expanding the therapeutic reach of the combined platform.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer